Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1129980 in Advanced Solid Tumors
NCT02134197Phase 1Terminated
- Sponsor
- Bayer
- Start
- May 2014
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lupartumab amadotin in solid tumor (advanced stage), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose at 21 days and Number of participants with adverse events up to 2 years. Started May 2014; status: terminated.
02
Drugs
Lupartumab amadotin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02134197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134197.